Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Both companies may succeed in this industry.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

Eli Lilly (NYSE: LLY) has been experiencing fantastic growth due to the success of its GLP-1 drugs, Mounjaro (approved for ...

Is there another beat-and-raise in the pharmaceutical giant's near future?

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive Specialties ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...